Context Therapeutics (NASDAQ:CNTX) Receives Outperform Rating from William Blair

William Blair reaffirmed their outperform rating on shares of Context Therapeutics (NASDAQ:CNTX - Free Report) in a report released on Tuesday,RTT News reports. William Blair also issued estimates for Context Therapeutics' Q1 2026 earnings at ($0.08) EPS, Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.08) EPS and Q4 2026 earnings at ($0.07) EPS.

Other equities research analysts have also recently issued reports about the stock. Citizens Jmp raised shares of Context Therapeutics to a "strong-buy" rating in a research report on Wednesday, January 8th. JMP Securities assumed coverage on Context Therapeutics in a report on Wednesday, January 8th. They set an "outperform" rating and a $4.00 target price on the stock. HC Wainwright restated a "buy" rating and issued a $5.00 price target on shares of Context Therapeutics in a research note on Friday, March 21st. Finally, D. Boral Capital reissued a "buy" rating and issued a $9.00 price objective on shares of Context Therapeutics in a report on Tuesday, April 29th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Buy" and an average target price of $6.17.

Context Therapeutics Price Performance

Shares of CNTX traded up $0.01 during midday trading on Tuesday, hitting $0.87. The stock had a trading volume of 30,000 shares, compared to its average volume of 300,208. The firm has a market cap of $78.01 million, a price-to-earnings ratio of -0.96 and a beta of 2.18. The company has a 50 day simple moving average of $0.78 and a two-hundred day simple moving average of $1.16. Context Therapeutics has a twelve month low of $0.55 and a twelve month high of $2.75.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last issued its quarterly earnings results on Thursday, March 20th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.01. Analysts forecast that Context Therapeutics will post -0.51 EPS for the current fiscal year.

Institutional Trading of Context Therapeutics

A number of hedge funds have recently modified their holdings of CNTX. MPM Bioimpact LLC bought a new position in Context Therapeutics in the 4th quarter valued at about $15,441,000. Franklin Resources Inc. lifted its holdings in Context Therapeutics by 115.9% during the 4th quarter. Franklin Resources Inc. now owns 4,003,380 shares of the company's stock worth $4,204,000 after purchasing an additional 2,149,392 shares during the last quarter. Allostery Investments LP bought a new stake in Context Therapeutics in the 4th quarter valued at $998,000. Blue Owl Capital Holdings LP increased its position in Context Therapeutics by 17.5% during the 4th quarter. Blue Owl Capital Holdings LP now owns 6,357,928 shares of the company's stock worth $6,676,000 after buying an additional 946,638 shares during the period. Finally, Renaissance Technologies LLC boosted its position in shares of Context Therapeutics by 412.8% in the fourth quarter. Renaissance Technologies LLC now owns 338,435 shares of the company's stock valued at $355,000 after acquiring an additional 272,435 shares during the period. Institutional investors and hedge funds own 14.03% of the company's stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.